晚期卵巢癌新辅助化疗后复发的MRI特征及基于化疗反应评分的列线图预测
回顾性分析101例接受新辅助化疗后间隔减瘤术的晚期卵巢癌患者,从附件和网膜病灶提取治疗前ADC直方图参数并结合化疗反应评分构建复发风险列线图。网膜熵、网膜化疗反应评分、残留肿瘤和新辅助化疗后Ki67为独立预测因子,列线图对1年、2年和3年复发预测的AUC分别为0.813、0.836和0.876,高风险组无复发生存期显著短于低风险组。
要点
- 网膜转移灶的术前ADC直方图参数对复发的预测价值优于原发附件肿瘤。
- 网膜熵是复发的独立预测因子(HR=0.378),并显著提升临床因素的预后价值。
- 网膜ADC参数与化疗反应评分相关(AUC=0.702),可作为治疗反应预测指标。
核心结论
- 网膜转移灶的术前ADC直方图分析较原发附件肿瘤具有更优的预测价值;整合影像标记与网膜化疗反应评分的列线图能有效分层复发风险,辅助个体化管理;网膜ADC参数与化疗反应评分相关,提示其可作为治疗反应的预测指标。
研究设计与样本
- 回顾性分析101例接受新辅助化疗后间隔减瘤术的晚期卵巢癌患者,从附件和网膜病灶提取ADC直方图参数,采用多因素Cox回归筛选独立预测因子构建复发风险列线图,并通过校准、ROC和决策曲线分析验证模型性能。
诊断标准与关键数值
- 网膜熵预测复发的HR=0.378(95%CI 0.187-0.762)。
- 网膜化疗反应评分预测复发的HR=0.437(95%CI 0.244-0.782)。
- 残留肿瘤预测复发的HR=2.419(95%CI 1.391-4.206)。
- 新辅助化疗后Ki67预测复发的HR=1.965(95%CI 1.145-3.374)。
- 列线图预测1年、2年和3年复发的AUC分别为0.813、0.836和0.876;网膜熵预测病理化疗反应的AUC=0.702。
临床应用与阅片要点
- 阅片时可关注网膜转移灶的ADC直方图参数(如熵值),其对新辅助化疗后复发的预测价值优于原发附件肿瘤。
- 列线图整合网膜熵、网膜化疗反应评分、残留肿瘤和新辅助化疗后Ki67,可用于分层复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate pretreatment ADC histogram parameters and chemotherapy response score (CRS) as recurrence predictors in advanced ovarian cancer (OC) treated with neoadjuvant chemotherapy (NACT).
MATERIALS AND METHODS: We retrospectively analyzed 101 advanced OC patients who underwent NACT followed by interval debulking surgery. ADC histogram parameters were extracted from adnexal and omental lesions. Multivariate Cox regression identified independent predictors to construct a recurrence risk nomogram. Model performance was validated via calibration, ROC, and decision curve analyses (DCA).
RESULTS: Multivariate analysis identified omental entropy (HR = 0.378; 95% CI, 0.187-0.762), omental CRS (HR = 0.437; 95% CI, 0.244-0.782), residual tumor (HR = 2.419; 95% CI, 1.391-4.206) and post-NACT Ki67 (HR = 1.965; 95% CI, 1.145-3.374) as independent predictors. The incorporation of omental entropy provided significant incremental prognostic value to clinical factors. The nomogram demonstrated good discrimination, with AUCs of 0.813, 0.836, and 0.876 achieved for 1-, 2-, and 3-year recurrence prediction. Patients stratified into the high-risk group exhibited significantly shorter recurrence-free survival than in the low-risk group (p < 0.001). DCA indicated good clinical application value of the model. Additionally, omental entropy served as a significant predictor of pathological chemotherapy response (AUC = 0.702).
CONCLUSIONS: Preoperative ADC histogram analysis of omental metastases demonstrated superior predictive value compared to primary adnexal tumors. The developed nomogram, integrating the imaging marker with omental CRS, effectively stratifies recurrence risk to guide personalized management. Additionally, omental ADC parameters correlate with CRS, suggesting their utility as predictors of treatment response.
引用
- Liu Y, Feng X, Zhou A, et al. MRI features and chemotherapy response score-based nomogram for post-neoadjuvant recurrence prediction in advanced ovarian cancer. Eur J Radiol. 2026. PMID: 41849870. doi:10.1016/j.ejrad.2026.112785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。